The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases

References

• Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med. 2010;14:457–487.
   PubMed Web of Science ®Google Scholar
• Kovacs GG. Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine. Int J Mol Sci. 2016;17:pii:E189.
   Web of Science ®Google Scholar
• Baldacci F, Lista S, Garaci F, et al. Biomarker-guided classification scheme of neurodegenerative diseases. J Sport Health Sci. 2016;5:383–387.
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology. 1984;34:939–944.
   PubMed Web of Science ®Google Scholar
• Baldacci F, Lista S, O’Bryant SE, et al. Blood-based biomarker screening with agnostic biological definitions for an accurate diagnosis within the dimensional spectrum of neurodegenerative diseases. Methods Mol Biol. 2018;1750:139–155.
   PubMedGoogle Scholar
• Kovacs GG, Milenkovic I, Wohrer A, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 2013;126:365–384.
   PubMed Web of Science ®Google Scholar
• Baldacci F, Lista S, Vergallo A, et al. A frontline defense against neurodegenerative diseases: the development of early disease detection methods. Expert Rev Mol Diagn. 2019;19:559–563.
   PubMed Web of Science ®Google Scholar
• Robinson JL, Lee EB, Xie SX, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141:2181–2193.
   PubMed Web of Science ®Google Scholar
• Hampel H, Toschi N, Babiloni C, et al. Revolution of Alzheimer precision neurology. passageway of systems biology and neurophysiology. J Alzheimers Dis. 2018;64:S47–s105.
   PubMed Web of Science ®Google Scholar
• Hampel H, O’Bryant SE, Durrleman S, et al. A precision medicine initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric J Int Menopause Soc. 2017;20:107–118.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr., Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dementia. 2018;14:535–562.
   PubMed Web of Science ®Google Scholar
• Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dementia. 2011;7:280–292.
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–746.
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9:1118–1127.
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–629.
   PubMed Web of Science ®Google Scholar
• Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dementia. 2011;7:270–279.
   PubMed Web of Science ®Google Scholar
• Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2015;30:1600–1611.
   PubMed Web of Science ®Google Scholar
• Swerdlow RH, Khan SM. A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease. Med Hypotheses. 2004;63:8–20.
   PubMed Web of Science ®Google Scholar
• Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer’s disease: progress to date and the path forward. Neuron. 2019;101:820–838.
   PubMed Web of Science ®Google Scholar
• Pimenova AA, Raj T, Goate AM. Untangling genetic risk for Alzheimer’s disease. Biol Psychiatry. 2018;83:300–310.
   PubMed Web of Science ®Google Scholar
• Freudenberg-Hua Y, Li W, Davies P. The role of genetics in advancing precision medicine for Alzheimer’s disease-a narrative review. Front Med (Lausanne). 2018;5:108.
   PubMed Web of Science ®Google Scholar
• Kamboh MI. A brief synopsis on the genetics of Alzheimer’s disease. Current Genet Med Rep. 2018;6:133–135.
   PubMedGoogle Scholar
• Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368:387–403.
   PubMed Web of Science ®Google Scholar
• Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet. 2016;388:505–517.
   PubMed Web of Science ®Google Scholar
• Jansen IE, Savage JE, Watanabe K, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet. 2019;51:404–413.
   PubMed Web of Science ®Google Scholar
• Zhang B, Gaiteri C, Bodea LG, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell. 2013;153:707–720.
   PubMed Web of Science ®Google Scholar
• Rabinovici GD, Carrillo MC, Forman M, et al. Multiple comorbid neuropathologies in the setting of Alzheimer’s disease neuropathology and implications for drug development. Alzheimer’s Dementia. 2017;3:83–91.
   Google Scholar
• Serrano-Pozo A, Frosch MP, Masliah E, et al. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.
   PubMed Web of Science ®Google Scholar
• Armstrong RA. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer’s disease. Folia Neuropathol. 2009;47:289–299.
   PubMed Web of Science ®Google Scholar
• Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;118:5–36.
   PubMed Web of Science ®Google Scholar
• Sanabria-Castro A, Alvarado-Echeverria I, Monge-Bonilla C. Molecular pathogenesis of Alzheimer’s disease: an update. Ann Neurosci. 2017;24:46–54.
   PubMed Web of Science ®Google Scholar
• McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Demen. 2011;7:263–269.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr., Bennett DA, Blennow K, et al. Contributors, NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–562.
   PubMed Web of Science ®Google Scholar
• Hampel H, Vergallo A, Aguilar LF, et al. Precision pharmacology for Alzheimer’s disease. Pharmacol Res. 2018;130:331–365.
   PubMed Web of Science ®Google Scholar
• Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol. 2017;13:457–476.
   PubMed Web of Science ®Google Scholar
• Crutch SJ, Lehmann M, Schott JM, et al. Posterior cortical atrophy. Lancet Neurol. 2012;11:170–178.
   PubMed Web of Science ®Google Scholar
• Crutch SJ, Schott JM, Rabinovici GD, et al. Consensus classification of posterior cortical atrophy. Alzheimers Dement. 2017;13:870–884.
   PubMed Web of Science ®Google Scholar
• Ossenkoppele R, Schonhaut DR, Baker SL, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol. 2015;77:338–342.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr., Bennett DA, Blennow K, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–547.
   PubMed Web of Science ®Google Scholar
• Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol. 2019;266:2075–2086.
   PubMed Web of Science ®Google Scholar
• Bevan-Jones RW, Cope TE, Jones SP, et al. [(18)F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion. Ann Clin Transl Neurol. 2018;5:1292–1296.
   PubMed Web of Science ®Google Scholar
• Twohig D, Nielsen HM. alpha-synuclein in the pathophysiology of Alzheimer’s disease. Mol Neurodegener. 2019;14:23.
   PubMed Web of Science ®Google Scholar
• Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3:812–818.
   PubMed Web of Science ®Google Scholar
• Shahnawaz M, Tokuda T, Waragai M, et al. Development of a biochemical diagnosis of Parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 2017;74:163–172.
   PubMed Web of Science ®Google Scholar
• Van Bulck M, Sierra-Magro A, Alarcon-Gil J, et al. Novel approaches for the treatment of Alzheimer’s and Parkinson’s disease. Int J Mol Sci. 2019;20:pii:E719.
   Web of Science ®Google Scholar
• O’Bryant SE. Blood biomarkers for use in Alzheimer disease-moving from “if” to “how?”. JAMA Neurol. DOI:10.1001/jamaneurol.2019.0845(2019)
   Web of Science ®Google Scholar
• Hart NJ, Koronyo Y, Black KL, et al. Ocular indicators of Alzheimer’s: exploring disease in the retina. Acta Neuropathol. 2016;132:767–787.
   PubMed Web of Science ®Google Scholar
• Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage. 2011;54(Suppl 1):S204–217.
   PubMed Web of Science ®Google Scholar
• Koronyo Y, Salumbides BC, Black KL, et al. Alzheimer’s disease in the retina: imaging retinal abeta plaques for early diagnosis and therapy assessment. Neurodegener Dis. 2012;10:285–293.
   PubMed Web of Science ®Google Scholar
• Koronyo Y, Biggs D, Barron E, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease. JCI Insight. 2017;2:pii:93621.
   Web of Science ®Google Scholar
• La Morgia C, Ross-Cisneros FN, Koronyo Y, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol. 2016;79:90–109.
   PubMed Web of Science ®Google Scholar
• Javaid FZ, Brenton J, Guo L, et al. Visual and ocular manifestations of Alzheimer’s disease and their use as biomarkers for diagnosis and progression. Front Neurol. 2016;7:55.
   PubMed Web of Science ®Google Scholar
• Katz B, Rimmer S, Iragui V, et al. Abnormal pattern electroretinogram in Alzheimer’s disease: evidence for retinal ganglion cell degeneration? Ann Neurol. 1989;26:221–225.
   PubMed Web of Science ®Google Scholar
• Yanagisawa D, Shirai N, Amatsubo T, et al. Relationship between the tautomeric structures of curcumin derivatives and their Abeta-binding activities in the context of therapies for Alzheimer’s disease. Biomaterials. 2010;31:4179–4185.
   PubMed Web of Science ®Google Scholar
• Andreasson U, Blennow K, Zetterberg H. Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimers Dement (Amst). 2016;3:98–102.
   PubMedGoogle Scholar
• Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature. 2018;554:249–254.
   PubMed Web of Science ®Google Scholar
• Nabers A, Perna L, Lange J, et al. Amyloid blood biomarker detects Alzheimer’s disease. EMBO Mol Med. 2018;10:pii:E8763.
   Web of Science ®Google Scholar
• Palmqvist S, Janelidze S, Stomrud E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol. DOI:10.1001/jamaneurol.2019.1632(2019)
   Web of Science ®Google Scholar
• Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimer’s Dementia. 2018;14:989–997.
   PubMed Web of Science ®Google Scholar
• Vergallo A, Megret L, Lista S, et al. Plasma amyloid beta 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer’s disease. Alzheimer’s Dementia. 2019;15:764–775.
   PubMed Web of Science ®Google Scholar
• Mattsson N, Andreasson U, Zetterberg H, et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74:557–566.
   PubMed Web of Science ®Google Scholar
• Hu H, Chen KL, Ou YN, et al. Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults. Aging (Albany NY). 2019;11:6904–6914.
   PubMedGoogle Scholar
• Mattsson N, Cullen NC, Andreasson U, et al. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76:791–799.
   PubMed Web of Science ®Google Scholar
• Keage HA, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol. 2009;9:3.
   PubMed Web of Science ®Google Scholar
• Carare RO, Hawkes CA, Jeffrey M, et al. Review: cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy. Neuropathol Appl Neurobiol. 2013;39:593–611.
   PubMed Web of Science ®Google Scholar
• Carare RO, Kalaria R. Cerebrovascular pathology: the dark side of neurodegeneration. Acta Neuropathol. 2016;131:641–643.
   PubMed Web of Science ®Google Scholar
• van Veluw SJ, Biessels GJ, Bouvy WH, et al. Cerebral amyloid angiopathy severity is linked to dilation of juxtacortical perivascular spaces. J Cereb Blood Flow and Metab. 2016;36:576–580.
   PubMed Web of Science ®Google Scholar
• Charidimou A, Martinez-Ramirez S, Shoamanesh A, et al. Cerebral amyloid angiopathy with and without hemorrhage: evidence for different disease phenotypes. Neurology. 2015;84:1206–1212.
   PubMed Web of Science ®Google Scholar
• Biffi A, Greenberg SM. Cerebral amyloid angiopathy: a systematic review. J Clin Neurol. 2011;7:1–9.
   PubMed Web of Science ®Google Scholar
• Greenberg SM, Rebeck GW, Vonsattel JP, et al. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995;38:254–259.
   PubMed Web of Science ®Google Scholar
• Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the boston criteria. Stroke. 2018;49:491–497.
   PubMed Web of Science ®Google Scholar
• Charidimou A, Boulouis G, Gurol ME, et al. Emerging concepts in sporadic cerebral amyloid angiopathy. Brain. 2017;140:1829–1850.
   PubMed Web of Science ®Google Scholar
• Charidimou A, Farid K, Baron JC. Amyloid-PET in sporadic cerebral amyloid angiopathy: a diagnostic accuracy meta-analysis. Neurology. 2017;89:1490–1498.
   PubMed Web of Science ®Google Scholar
• Charidimou A, Farid K, Tsai HH, et al. Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance. J Neurol Neurosurg Psychiatry. 2018;89:410–417.
   PubMed Web of Science ®Google Scholar
• Charidimou A, Friedrich JO, Greenberg SM, et al. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: a meta-analysis. Neurology. 2018;90:e754–e762.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Gagnon JF, Bertrand JA, et al. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology. 2015;84:1104–1113.
   PubMed Web of Science ®Google Scholar
• Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:745–752.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184.
   PubMed Web of Science ®Google Scholar
• Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33–39.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology. 2001;57:1497–1499.
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Very old onset parkinsonism: a clinical-pathological study. Parkinsonism Relat Disord. 2018;57:39–43.
   PubMed Web of Science ®Google Scholar
• Fereshtehnejad SM, Montplaisir JY, Pelletier A, et al. Validation of the MDS research criteria for prodromal Parkinson’s disease: longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. Mov Disord. 2017;32:865–873.
   PubMed Web of Science ®Google Scholar
• Cosottini M, Frosini D, Pesaresi I, et al. Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease. AJNR Am J Neuroradiol. 2015;36:461–466.
   PubMed Web of Science ®Google Scholar
• Berg D, Behnke S, Seppi K, et al. Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson’s disease. Mov Disord. 2013;28:216–219.
   PubMed Web of Science ®Google Scholar
• Tao A, Chen G, Deng Y, et al. Accuracy of transcranial sonography of the substantia nigra for detection of Parkinson’s disease: a systematic review and meta-analysis. Ultrasound Med Biol. 2019;45:628–641.
   PubMed Web of Science ®Google Scholar
• Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75:1055–1061.
   PubMed Web of Science ®Google Scholar
• Terrelonge M Jr., Marder KS, Weintraub D, et al. CSF beta-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. J Mol Neurosci. 2016;58:88–92.
   PubMed Web of Science ®Google Scholar
• Rochester L, Galna B, Lord S, et al. Decrease in Abeta42 predicts dopa-resistant gait progression in early Parkinson disease. Neurology. 2017;88:1501–1511.
   PubMed Web of Science ®Google Scholar
• Ffytche DH, Pereira JB, Ballard C, et al. Risk factors for early psychosis in PD: insights from the Parkinson’s progression markers initiative. J Neurol Neurosurg Psychiatry. 2017;88:325–331.
   PubMed Web of Science ®Google Scholar
• Constantinides VC, Paraskevas GP, Emmanouilidou E, et al. CSF biomarkers beta-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. J Neurol Sci. 2017;382:91–95.
   PubMed Web of Science ®Google Scholar
• Gao L, Tang H, Nie K, et al. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson’s disease diagnosis: a systematic review and meta-analysis. Int J Neurosci. 2015;125:645–654.
   PubMed Web of Science ®Google Scholar
• Eusebi P, Giannandrea D, Biscetti L, et al. Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2017;32:1389–1400.
   PubMed Web of Science ®Google Scholar
• Zhou B, Wen M, Yu WF, et al. The diagnostic and differential diagnosis utility of cerebrospinal fluid alpha -synuclein levels in Parkinson’s disease: a meta-analysis. Parkinson’s Dis. 2015;2015:567386.
   PubMed Web of Science ®Google Scholar
• Kalia LV. Diagnostic biomarkers for Parkinson’s disease: focus on alpha-synuclein in cerebrospinal fluid. Parkinsonism Relat Disord. 2019;59:21–25.
   PubMed Web of Science ®Google Scholar
• Hall S, Surova Y, Ohrfelt A, et al. Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s disease. Mov Disord. 2016;31:898–905.
   PubMed Web of Science ®Google Scholar
• Pagano G, De Micco R, Yousaf T, et al. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology. 2018;91:e894–e905.
   PubMed Web of Science ®Google Scholar
• Backstrom DC, Eriksson Domellof M, Linder J, et al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. 2015;72:1175–1182.
   PubMed Web of Science ®Google Scholar
• Ge F, Ding J, Liu Y, et al. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis. Neurosci Lett. 2018;685:35–41.
   PubMed Web of Science ®Google Scholar
• Bridel C, van Wieringen WN, Zetterberg H, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. DOI:10.1001/jamaneurol.2019.1534(2019)
   Web of Science ®Google Scholar
• Hansson O, Janelidze S, Hall S, et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88:930–937.
   PubMed Web of Science ®Google Scholar
• Marques TM, van Rumund A, Oeckl P, et al. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology. 2019;92:e1479–e1486.
   PubMed Web of Science ®Google Scholar
• Colom-Cadena M, Grau-Rivera O, Planellas L, et al. Regional overlap of pathologies in Lewy body disorders. J Neuropathol Exp Neurol. 2017;76:216–224.
   PubMed Web of Science ®Google Scholar
• Irwin DJ, Xie SX, Coughlin D, et al. CSF tau and beta-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology. 2018;90:e1038–e1046.
   PubMed Web of Science ®Google Scholar
• Parnetti L, Paciotti S, Farotti L, et al. Parkinson’s and Lewy body dementia CSF biomarkers. Clin Chim Acta. 2019;495:318–325.
   PubMed Web of Science ®Google Scholar
• McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89:88–100.
   PubMed Web of Science ®Google Scholar
• McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863–1872.
   PubMed Web of Science ®Google Scholar
• Abdelnour C, van Steenoven I, Londos E, et al. Alzheimer’s disease cerebrospinal fluid biomarkers predict cognitive decline in Lewy body dementia. Mov Disord. 2016;31:1203–1208.
   PubMed Web of Science ®Google Scholar
• Sako W, Murakami N, Izumi Y, et al. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. Mov Disord. 2014;29:1599–1605.
   PubMed Web of Science ®Google Scholar
• Joutsa J, Gardberg M, Roytta M, et al. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord. 2014;20:840–844.
   PubMed Web of Science ®Google Scholar
• Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853–864.
   PubMed Web of Science ®Google Scholar
• Ali F, Martin PR, Botha H, et al. Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. Mov Disord. 2019;34:1144–1153.
   PubMed Web of Science ®Google Scholar
• Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1–9.
   PubMed Web of Science ®Google Scholar
• Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology. 2008;246:214–221.
   PubMed Web of Science ®Google Scholar
• Hussl A, Mahlknecht P, Scherfler C, et al. Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson’s disease and the Parkinson variant of multiple system atrophy. Mov Disord. 2010;25:2444–2449.
   PubMed Web of Science ®Google Scholar
• Longoni G, Agosta F, Kostic VS, et al. MRI measurements of brainstem structures in patients with Richardson’s syndrome, progressive supranuclear palsy-parkinsonism, and Parkinson’s disease. Mov Disord. 2011;26:247–255.
   PubMed Web of Science ®Google Scholar
• Moller L, Kassubek J, Sudmeyer M, et al. Manual MRI morphometry in Parkinsonian syndromes. Mov Disord. 2017;32:778–782.
   PubMed Web of Science ®Google Scholar
• Frosini D, Ceravolo R, Tosetti M, et al. Nigral involvement in atypical parkinsonisms: evidence from a pilot study with ultra-high field MRI. J Neural Transm. 2016;123:509–513.
   PubMed Web of Science ®Google Scholar
• Sjostrom H, Granberg T, Westman E, et al. Quantitative susceptibility mapping differentiates between parkinsonian disorders. Parkinsonism Relat Disord. 2017;44:51–57.
   PubMed Web of Science ®Google Scholar
• Mazzucchi S, Frosini D, Costagli M, et al. Quantitative susceptibility mapping in atypical Parkinsonisms. Neuroimage Clin. 2019;24:101999.
   PubMed Web of Science ®Google Scholar
• Donker Kaat L, Meeter LH, Chiu WZ, et al. Serum neurofilament light chain in progressive supranuclear palsy. Parkinsonism Relat Disord. 2018;56:98–101.
   PubMed Web of Science ®Google Scholar
• Rojas JC, Karydas A, Bang J, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016;3:216–225.
   PubMed Web of Science ®Google Scholar
• Ling H, O’Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010;133:2045–2057.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503.
   PubMed Web of Science ®Google Scholar
• Alexander SK, Rittman T, Xuereb JH, et al. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry. 2014;85:925–929.
   PubMed Web of Science ®Google Scholar
• Sakae N, Josephs KA, Litvan I, et al. Clinicopathologic subtype of Alzheimer’s disease presenting as corticobasal syndrome. Alzheimer’s Dementia. 2019;15:1218–1228.
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Rossi C, Cilia R, et al. Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: a SPECT follow-up study. Parkinsonism Relat Disord. 2013;19:557–559.
   PubMed Web of Science ®Google Scholar
• Svenningsson P. Corticobasal degeneration: advances in clinicopathology and biomarkers. Curr Opin Neurol. 2019;32:597–603.
   PubMed Web of Science ®Google Scholar
• Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670–676.
   PubMed Web of Science ®Google Scholar
• Miki Y, Foti SC, Asi YT, et al. Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. Brain. 2019;142:2813–2827.
   PubMed Web of Science ®Google Scholar
• Massey LA, Micallef C, Paviour DC, et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2012;27:1754–1762.
   PubMed Web of Science ®Google Scholar
• Kim JM, Jeong HJ, Bae YJ, et al. Loss of substantia nigra hyperintensity on 7 tesla MRI of Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Parkinsonism Relat Disord. 2016;26:47–54.
   PubMed Web of Science ®Google Scholar
• Koga S, Aoki N, Uitti RJ, et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology. 2015;85:404–412.
   PubMed Web of Science ®Google Scholar
• Ratnavalli E, Brayne C, Dawson K, et al. The prevalence of frontotemporal dementia. Neurology. 2002;58:1615–1621.
   PubMed Web of Science ®Google Scholar
• Rohrer JD, Guerreiro R, Vandrovcova J, et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73:1451–1456.
   PubMed Web of Science ®Google Scholar
• Le Ber I. Genetics of frontotemporal lobar degeneration: an up-date and diagnosis algorithm. Rev Neurol (Paris). 2013;169:811–819.
   PubMed Web of Science ®Google Scholar
• Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386:1672–1682.
   PubMed Web of Science ®Google Scholar
• Johnson JK, Diehl J, Mendez MF, et al. Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol. 2005;62:925–930.
   PubMed Web of Science ®Google Scholar
• Snowden J, Neary D, Mann D. Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol. 2007;114:31–38.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111–113.
   PubMed Web of Science ®Google Scholar
• Lee EB, Porta S, Michael Baer G, et al. Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. 2017;134:65–78.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1–4.
   PubMed Web of Science ®Google Scholar
• Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–2477.
   PubMed Web of Science ®Google Scholar
• Pasquier F, Richard F, Lebert F. Natural history of frontotemporal dementia: comparison with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2004;17:253–257.
   PubMed Web of Science ®Google Scholar
• Rascovsky K, Salmon DP, Lipton AM, et al. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology. 2005;65:397–403.
   PubMed Web of Science ®Google Scholar
• Garcin B, Lillo P, Hornberger M, et al. Determinants of survival in behavioral variant frontotemporal dementia. Neurology. 2009;73:1656–1661.
   PubMed Web of Science ®Google Scholar
• Grimmer T, Wutz C, Alexopoulos P, et al. Visual versus fully automated analyses of 18F-FDG and amyloid pet for prediction of dementia due to Alzheimer disease in mild cognitive impairment. J Nucl Med. 2016;57:204–207.
   PubMed Web of Science ®Google Scholar
• Arbizu J, Festari C, Altomare D, et al. Clinical utility of FDG-PET for the clinical diagnosis in MCI. Eur J Nucl Med Mol Imaging. 2018;45:1497–1508.
   PubMed Web of Science ®Google Scholar
• Engler H, Santillo AF, Wang SX, et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging. 2008;35:100–106.
   PubMed Web of Science ®Google Scholar
• Harris JM, Gall C, Thompson JC, et al. Sensitivity and specificity of FTDC criteria for behavioral variant frontotemporal dementia. Neurology. 2013;80:1881–1887.
   PubMed Web of Science ®Google Scholar
• Vijverberg EG, Dols A, Krudop WA, et al. Diagnostic accuracy of the frontotemporal dementia consensus criteria in the late-onset frontal lobe syndrome. Dement Geriatr Cogn Disord. 2016;41:210–219.
   PubMed Web of Science ®Google Scholar
• Burrell JR, Kiernan MC, Vucic S, et al. Motor neuron dysfunction in frontotemporal dementia. Brain. 2011;134:2582–2594.
   PubMed Web of Science ®Google Scholar
• Lillo P, Garcin B, Hornberger M, et al. Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. Arch Neurol. 2010;67:826–830.
   PubMed Web of Science ®Google Scholar
• Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59:1077–1079.
   PubMed Web of Science ®Google Scholar
• Le Ber I, Guedj E, Gabelle A, et al. Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain. 2006;129:3051–3065.
   PubMed Web of Science ®Google Scholar
• Kertesz A, McMonagle P, Blair M, et al. The evolution and pathology of frontotemporal dementia. Brain. 2005;128:1996–2005.
   PubMed Web of Science ®Google Scholar
• Woolley JD, Khan BK, Murthy NK, et al. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry. 2011;72:126–133.
   PubMed Web of Science ®Google Scholar
• Nascimento C, Nunes VP, Diehl Rodriguez R, et al. A review on shared clinical and molecular mechanisms between bipolar disorder and frontotemporal dementia. Prog Neuropsychopharmacol Biol Psychiatry. 2019;93:269–283.
   PubMed Web of Science ®Google Scholar
• Kipps CM, Hodges JR, Hornberger M. Nonprogressive behavioural frontotemporal dementia: recent developments and clinical implications of the ‘bvFTD phenocopy syndrome’. Curr Opin Neurol. 2010;23:628–632.
   PubMed Web of Science ®Google Scholar
• Baker M, Mackenzie IR, Pickering-Brown SM. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916–919.
   PubMed Web of Science ®Google Scholar
• Meeter LH, Kaat LD, Rohrer JD, et al. Imaging and fluid biomarkers in frontotemporal dementia. Nat Rev Neurol. 2017;13:406–419.
   PubMed Web of Science ®Google Scholar
• Mahoney CJ, Ridgway GR, Malone IB, et al. Profiles of white matter tract pathology in frontotemporal dementia. Hum Brain Mapp. 2014;35:4163–4179.
   PubMed Web of Science ®Google Scholar
• Mahoney CJ, Simpson IJ, Nicholas JM. Longitudinal diffusion tensor imaging in frontotemporal dementia. Ann Neurol. 2015;77:33–46.
   PubMed Web of Science ®Google Scholar
• McMillan CT, Irwin DJ, Avants BB, et al. White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2013;84:949–955.
   PubMed Web of Science ®Google Scholar
• Rohrer JD, Nicholas JM, Cash DM, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the genetic frontotemporal dementia initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol. 2015;14:253–262.
   PubMed Web of Science ®Google Scholar
• Lee SE, Sias AC, Mandelli ML, et al. Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. NeuroImage Clin. 2017;14:286–297.
   PubMed Web of Science ®Google Scholar
• Zhou J, Greicius MD, Gennatas ED, et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer’s disease. Brain. 2010;133:1352–1367.
   PubMed Web of Science ®Google Scholar
• Filippi M, Agosta F, Scola E, et al. Functional network connectivity in the behavioral variant of frontotemporal dementia. Cortex. 2013;49:2389–2401.
   PubMed Web of Science ®Google Scholar
• Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology. 2008;70:1827–1835.
   PubMed Web of Science ®Google Scholar
• Paterson RW, Slattery CF, Poole T, et al. Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimer’s Res Ther. 2018;10:32.
   PubMed Web of Science ®Google Scholar
• Katisko K, Cajanus A, Korhonen T, et al. Prodromal and early bvFTD: evaluating clinical features and current biomarkers. Front Neurosci. 2019;13:658.
   PubMed Web of Science ®Google Scholar
• Zetterberg H, van Swieten JC, Boxer AL, et al. Review: fluid biomarkers for frontotemporal dementias. Neuropathol Appl Neurobiol. 2019;45:81–87.
   PubMed Web of Science ®Google Scholar
• Pijnenburg YA, Verwey NA, van der Flier WM, et al. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst). 2015;1:505–512.
   PubMedGoogle Scholar
• Niikado M, Chrem-Mendez P, Itzcovich T, et al. Evaluation of cerebrospinal fluid neurofilament light chain as a routine biomarker in a memory clinic. J Gerontol A Biol Sci Med Sci. 2019;74:442–445.
   PubMed Web of Science ®Google Scholar
• Rohrer JD, Woollacott IO, Dick KM, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87:1329–1336.
   PubMed Web of Science ®Google Scholar
• Skillback T, Farahmand B, Bartlett JW, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014;83:1945–1953.
   PubMed Web of Science ®Google Scholar
• Skillback T, Mattsson N, Blennow K, et al. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:397–403.
   PubMed Web of Science ®Google Scholar
• Meeter LH, Dopper EG, Jiskoot LC, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016;3:623–636.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Anderl-Straub S, Diehl-Schmid J, et al. Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology. 2018;91:e1390–e1401.
   PubMed Web of Science ®Google Scholar
• Sjogren M, Rosengren L, Minthon L, et al. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology. 2000;54:1960–1964.
   PubMed Web of Science ®Google Scholar
• de Jong D, Jansen RW, Pijnenburg YA, et al. CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry. 2007;78:936–938.
   PubMed Web of Science ®Google Scholar
• Al Shweiki MR, Steinacker P, Oeckl P, et al. Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. J Psychiatr Res. 2019;113:137–140.
   PubMed Web of Science ®Google Scholar
• Wilke C, Preische O, Deuschle C, et al. Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J Neurol Neurosurg Psychiatry. 2016;87:1270–1272.
   PubMed Web of Science ®Google Scholar
• Perry DC, Brown JA, Possin KL, et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain. 2017;140:3329–3345.
   PubMed Web of Science ®Google Scholar
• Meeter LHH, Gendron TF, Sias AC, et al. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann Clin Transl Neurol. 2018;5:583–597.
   PubMed Web of Science ®Google Scholar
• Ghidoni R, Benussi L, Glionna M, et al. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology. 2008;71:1235–1239.
   PubMed Web of Science ®Google Scholar
• Morenas-Rodriguez E, Cervera-Carles L, Vilaplana E, et al. Progranulin protein levels in cerebrospinal fluid in primary neurodegenerative dementias. J Alzheimers Dis. 2016;50:539–546.
   PubMed Web of Science ®Google Scholar
• Meeter LH, Patzke H, Loewen G, et al. Progranulin levels in plasma and cerebrospinal fluid in granulin mutation carriers. Dement Geriatr Cogn Dis Extra. 2016;6:330–340.
   PubMed Web of Science ®Google Scholar
• Ghidoni R, Stoppani E, Rossi G, et al. Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: a multicenter Italian study. Neurodegener Dis. 2012;9:121–127.
   PubMed Web of Science ®Google Scholar
• Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916–919.
   PubMed Web of Science ®Google Scholar
• Magnin E, Demonet JF, Wallon D, et al. Primary progressive aphasia in the network of french alzheimer plan memory centers. J Alzheimers Dis. 2016;54:1459–1471.
   PubMed Web of Science ®Google Scholar
• Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–1014.
   PubMed Web of Science ®Google Scholar
• Mesulam MM. Primary progressive aphasia. Ann Neurol. 2001;49:425–432.
   PubMed Web of Science ®Google Scholar
• Matias-Guiu JA, Cabrera-Martin MN, Moreno-Ramos T, et al. Clinical course of primary progressive aphasia: clinical and FDG-PET patterns. J Neurol. 2015;262:570–577.
   PubMed Web of Science ®Google Scholar
• Spinelli EG, Mandelli ML, Miller ZA, et al. Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol. 2017;81:430–443.
   PubMed Web of Science ®Google Scholar
• Chare L, Hodges JR, Leyton CE, et al. New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. J Neurol Neurosurg Psychiatry. 2014;85:865–870.
   PubMed Web of Science ®Google Scholar
• Harris JM, Gall C, Thompson JC, et al. Classification and pathology of primary progressive aphasia. Neurology. 2013;81:1832–1839.
   PubMed Web of Science ®Google Scholar
• Bergeron D, Gorno-Tempini ML, Rabinovici GD, et al. Prevalence of amyloid-beta pathology in distinct variants of primary progressive aphasia. Ann Neurol. 2018;84:729–740.
   PubMed Web of Science ®Google Scholar
• Ramos EM, Dokuru DR, Van Berlo V, et al. Genetic screen in a large series of patients with primary progressive aphasia. Alzheimer’s Dementia. 2019;15:553–560.
   PubMed Web of Science ®Google Scholar
• Chan D, Fox NC, Scahill RI, et al. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer’s disease. Ann Neurol. 2001;49:433–442.
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Weintraub S, Rogalski EJ, et al. Asymmetry and heterogeneity of Alzheimer’s and frontotemporal pathology in primary progressive aphasia. Brain. 2014;137:1176–1192.
   PubMed Web of Science ®Google Scholar
• Gorno-Tempini ML, Brambati SM, Ginex V, et al. The logopenic/phonological variant of primary progressive aphasia. Neurology. 2008;71:1227–1234.
   PubMed Web of Science ®Google Scholar
• Rohrer JD, Ridgway GR, Crutch SJ, et al. Progressive logopenic/phonological aphasia: erosion of the language network. NeuroImage. 2010;49:984–993.
   PubMed Web of Science ®Google Scholar
• Seeley WW, Crawford RK, Zhou J, et al. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42–52.
   PubMed Web of Science ®Google Scholar
• Santangelo R, Coppi E, Ferrari L, et al. Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia. J Alzheimers Dis. 2015;43:1429–1440.
   PubMed Web of Science ®Google Scholar
• Paraskevas GP, Kasselimis D, Kourtidou E, et al. Cerebrospinal fluid biomarkers as a diagnostic tool of the underlying pathology of primary progressive aphasia. J Alzheimers Dis. 2017;55:1453–1461.
   PubMed Web of Science ®Google Scholar
• Norise C, Ungrady M, Halpin A, et al. Clinical correlates of Alzheimer’s disease cerebrospinal fluid analytes in primary progressive aphasia. Front Neurol. 2019;10:485.
   PubMed Web of Science ®Google Scholar
• Agosta F, Scola E, Canu E, et al. White matter damage in frontotemporal lobar degeneration spectrum. Cereb Cortex. 2012;22:2705–2714.
   PubMed Web of Science ®Google Scholar
• Agosta F, Galantucci S, Valsasina P, et al. Disrupted brain connectome in semantic variant of primary progressive aphasia. Neurobiol Aging. 2014;35:2646–2655.
   PubMed Web of Science ®Google Scholar
• Meeter LHH, Vijverberg EG, Del Campo M, et al. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology. 2018;90:e1231–e1239.
   PubMed Web of Science ®Google Scholar
• Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75:116–126.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Semler E, Anderl-Straub S, et al. Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology. 2017;88:961–969.
   PubMed Web of Science ®Google Scholar
• Hannibal L. Nitric oxide homeostasis in neurodegenerative diseases. Curr Alzheimer Res. 2016;13:135–149.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Hardiman O, Kiernan MC, et al. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15:1182–1194.
   PubMed Web of Science ®Google Scholar
• van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–2098.
   PubMed Web of Science ®Google Scholar
• Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:153–174.
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–133.
   PubMed Web of Science ®Google Scholar
• Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.
   PubMed Web of Science ®Google Scholar
• Chia R, Chio A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17:94–102.
   PubMed Web of Science ®Google Scholar
• Chio A, Traynor BJ. Motor neuron disease in 2014. Biomarkers for ALS–in search of the Promised Land. Nat Rev Neurol. 2015;11:72–74.
   PubMed Web of Science ®Google Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis”workshop contributors. J Neurol Sci. 1994;124(Suppl):96–107.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis and other motor neuron disorders. 2000;1:293–299.
   Google Scholar
• de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119:497–503.
   PubMed Web of Science ®Google Scholar
• Carvalho MD, Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler. 2009;10:53–57.
   PubMed Web of Science ®Google Scholar
• Geevasinga N, Menon P, Scherman DB, et al. Diagnostic criteria in amyotrophic lateral sclerosis: A multicenter prospective study. Neurology. 2016;87:684–690.
   PubMed Web of Science ®Google Scholar
• Phukan J, Elamin M, Bede P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2012;83:102–108.
   PubMed Web of Science ®Google Scholar
• Strong MJ. The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9:323–338.
   PubMed Web of Science ®Google Scholar
• Strong MJ, Grace GM, Freedman M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10:131–146.
   PubMed Web of Science ®Google Scholar
• Tan RH, Guennewig B, Dobson-Stone C, et al. The underacknowledged PPA-ALS: A unique clinicopathologic subtype with strong heritability. Neurology. 2019;92:e1354–e1366.
   PubMed Web of Science ®Google Scholar
• Iazzolino B, Pain D, Peotta L, et al. Validation of the revised classification of cognitive and behavioural impairment in ALS. J Neurol Neurosurg Psychiatry. 2019;90:734–739.
   PubMed Web of Science ®Google Scholar
• Sabatelli M, Marangi G, Conte A, et al. New ALS-related genes expand the spectrum paradigm of amyotrophic lateral sclerosis. Brain Pathol. 2016;26:266–275.
   PubMed Web of Science ®Google Scholar
• McCluskey L, Vandriel S, Elman L, et al. ALS-Plus syndrome: non-pyramidal features in a large ALS cohort. J Neurol Sci. 2014;345:118–124.
   PubMed Web of Science ®Google Scholar
• Brooks BR. ALS-Plus - where does it begin, where does it end? J Neurol Sci. 2014;345:1–2.
   PubMed Web of Science ®Google Scholar
• Toschi N, Lista S, Baldacci F, et al. Biomarker-guided clustering of Alzheimer’s disease clinical syndromes. Neurobiol Aging. 2019;83:42–53.
   PubMed Web of Science ®Google Scholar
• Blasco H, Vourc’h P, Pradat PF, et al. Further development of biomarkers in amyotrophic lateral sclerosis. Expert Rev Mol Diagn. 2016;16:853–868.
   PubMed Web of Science ®Google Scholar
• Endo H, Sekiguchi K, Shimada H, et al. Low signal intensity in motor cortex on susceptibility-weighted MR imaging is correlated with clinical signs of amyotrophic lateral sclerosis: a pilot study. J Neurol. 2018;265:552–561.
   PubMed Web of Science ®Google Scholar
• Verber NS, Shepheard SR, Sassani M, et al. Biomarkers in motor neuron disease: a state of the art review. Front Neurol. 2019;10:291.
   PubMed Web of Science ®Google Scholar
• Ellis CM, Simmons A, Andrews C, et al. A proton magnetic resonance spectroscopic study in ALS: correlation with clinical findings. Neurology. 1998;51:1104–1109.
   PubMed Web of Science ®Google Scholar
• Schuff N, Rooney WD, Miller R, et al. Reanalysis of multislice (1)H MRSI in amyotrophic lateral sclerosis. Magn Reson Med. 2001;45:513–516.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Ulug AM, Pullman SL, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology. 2007;68:1402–1410.
   PubMed Web of Science ®Google Scholar
• Agosta F, Spinelli EG, Filippi M. Neuroimaging in amyotrophic lateral sclerosis: current and emerging uses. Expert Rev Neurother. 2018;18:395–406.
   PubMed Web of Science ®Google Scholar
• Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870–881.
   PubMed Web of Science ®Google Scholar
• Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577–589.
   PubMed Web of Science ®Google Scholar
• Blennow K. A review of fluid biomarkers for Alzheimer’s disease: moving from CSF to blood. Neurol Ther. 2017;6:15–24.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016;54:1655–1661.
   PubMed Web of Science ®Google Scholar
• Poesen K, De Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88:2302–2309.
   PubMed Web of Science ®Google Scholar
• Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90:e22–e30.
   PubMed Web of Science ®Google Scholar
• Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247–2257.
   PubMed Web of Science ®Google Scholar
• Gaiani A, Martinelli I, Bello L, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. 2017;74:525–532.
   PubMed Web of Science ®Google Scholar
• Baldacci F, Lista S, Palermo G, et al. The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. Expert Rev Proteomics. 2019;16:593–600.
   PubMed Web of Science ®Google Scholar
• Thompson AG, Gray E, Thezenas ML, et al. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol. 2018;83:258–268.
   PubMed Web of Science ®Google Scholar
• Illan-Gala I, Alcolea D, Montal V, et al. CSF sAPPbeta, YKL-40, and NfL along the ALS-FTD spectrum. Neurology. 2018;91:e1619–e1628.
   PubMed Web of Science ®Google Scholar
• Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:157–164.
   PubMed Web of Science ®Google Scholar
• Thouvenot E, Demattei C, Lehmann S, et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. 2020;27:251–257.
   PubMed Web of Science ®Google Scholar
• Gille B, De Schaepdryver M, Goossens J, et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathol Appl Neurobiol. 2019;45:291–304.
   PubMed Web of Science ®Google Scholar
• Hampel H, O’Bryant SE, Molinuevo JL, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. 2018;14:639–652.
   PubMed Web of Science ®Google Scholar
• Candelise N, Schmitz M, Da Silva Correia SM, et al. Applications of the real-time quaking-induced conversion assay in diagnosis, prion strain-typing, drug pre-screening and other amyloidopathies. Expert Rev Mol Diagn. 2017;17:897–904.
   PubMed Web of Science ®Google Scholar
• Asai H, Ikezu S, Tsunoda S, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18:1584–1593.
   PubMed Web of Science ®Google Scholar
• Fiandaca MS, Kapogiannis D, Mapstone M, et al. Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimer’s Dementia. 2015;11:600–607.e601.
   PubMed Web of Science ®Google Scholar
• Goetzl EJ, Boxer A, Schwartz JB, et al. Low neural exosomal levels of cellular survival factors in Alzheimer’s disease. Ann Clin Transl Neurol. 2015;2:769–773.
   PubMed Web of Science ®Google Scholar
• Hamlett ED, Goetzl EJ, Ledreux A, et al. Neuronal exosomes reveal Alzheimer’s disease biomarkers in Down syndrome. Alzheimer’s Dementia. 2017;13:541–549.
   PubMed Web of Science ®Google Scholar
• Coleman BM, Hill AF. Extracellular vesicles–Their role in the packaging and spread of misfolded proteins associated with neurodegenerative diseases. Semin Cell Dev Biol. 2015;40:89–96.
   PubMed Web of Science ®Google Scholar
• Kumar S, Reddy PH. Are circulating microRNAs peripheral biomarkers for Alzheimer’s disease? Biochim Biophys Acta. 2016;1862:1617–1627.
   PubMed Web of Science ®Google Scholar
• D’Anca M, Fenoglio C, Serpente M, et al. Exosome determinants of physiological aging and age-related neurodegenerative diseases. Front Aging Neurosci. 2019;11:232.
   PubMed Web of Science ®Google Scholar
• Jain G, Stuendl A, Rao P, et al. A combined miRNA-piRNA signature to detect Alzheimer’s disease. Transl Psychiatry. 2019;9:250.
   PubMed Web of Science ®Google Scholar
• Hampel H, Lista S, Neri C, et al. Time for the systems-level integration of aging: resilience enhancing strategies to prevent Alzheimer’s disease. Prog Neurobiol. 2019;181:101662.
   PubMed Web of Science ®Google Scholar
• Perez-Nievas BG, Stein TD, Tai HC, et al. Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology. Brain. 2013;136:2510–2526.
   PubMed Web of Science ®Google Scholar
• Dourlen P, Kilinc D, Malmanche N, et al. The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? Acta Neuropathol. 2019;138:221–236.
   PubMed Web of Science ®Google Scholar
• Castrillo JI, Lista S, Hampel H, et al. systems biology methods for Alzheimer’s disease research toward molecular signatures, subtypes, and stages and precision medicine: application in cohort studies and trials. Methods Mol Biol. 2018;1750:31–66.
   PubMedGoogle Scholar
• Castrillo JI, Oliver SG. Alzheimer’s as a systems-level disease involving the interplay of multiple cellular networks. Methods Mol Biol. 2016;1303:3–48.
   PubMedGoogle Scholar
• Cummings J, Fox N, Vellas B, et al. Biomarker and clinical trial design support for disease-modifying therapies: report of a survey of the EU/US: Alzheimer’s disease task force. J Prev Alzheimer’s Dis. 2018;5:103–109.
   PubMed Web of Science ®Google Scholar
• Kozakov D, Hall DR, Napoleon RL, et al. New frontiers in druggability. J Med Chem. 2015;58:9063–9088.
   PubMed Web of Science ®Google Scholar
• Wu F, Ma C, Tan C. Network motifs modulate druggability of cellular targets. Sci Rep. 2016;6:36626.
   PubMed Web of Science ®Google Scholar
• Elman JA, Oh H, Madison CM, et al. Neural compensation in older people with brain amyloid-beta deposition. Nat Neurosci. 2014;17:1316–1318.
   PubMed Web of Science ®Google Scholar
• Geerts H, Dacks PA, Devanarayan V, et al. Big data to smart data in Alzheimer’s disease: the brain health modeling initiative to foster actionable knowledge. Alzheimers Dement. 2016;12:1014–1021.
   PubMed Web of Science ®Google Scholar
• Haas M, Stephenson D, Romero K, et al. Big data to smart data in Alzheimer’s disease: real-world examples of advanced modeling and simulation. Alzheimers Dement. 2016;12:1022–1030.
   PubMed Web of Science ®Google Scholar